Spectral Medical Provides Update on Tigris Clinical Trial

Robust recruitment activities experienced in closing weeks of September 44 patients now enrolled TORONTO, Canada – October 4, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for...
Read More

Spectral Medical Provides Update on Tigris Clinical Trial

Provides positive case study on patient enrolled at University of Michigan 14 clinical sites actively enrolling patients with 40 patients now randomized TORONTO, Canada – July 20, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage...
Read More
Click to Hide Advanced Floating Content
EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.